Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Molecular Partners (MOLN)
NASDAQ:MOLN
RESEARCH TOOLSreports
Holding MOLN?
Track your performance easily
MOLN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.32 - $12.70
Previous Close$5.18
Volume8.22K
Average Volume (3M)17.25K
Market Cap
$184.68M
Enterprise Value-$29.93M
Total Cash (Recent Filing)CHF186.89M
Total Debt (Recent Filing)CHF3.65M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Mar 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding36,354,297
10 Day Avg. Volume11,827
30 Day Avg. Volume17,253
Standard Deviation0.24
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.98
Price to Sales (P/S)146.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.70Price Target Upside62.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Molecular Partners News
PremiumCompany Announcements
Molecular Partners Advances Therapeutic Platforms
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyThe company reported additional signals of clinical efficacy with MP0533, some evidence of dose response, and good enough tolerability to proceed to higher dose levels.
Mechanism Of ActionEngaging single-TAA expressing blasts will broaden MP033’s killing potential and support a new MoA thesis for MP0533 – broadest CD3 TCE as competitors target one TAA at a time.
Patient OutcomesSeven of the nine patients in dose regimen cohort 6 are continuing treatment, and one patient is in a morphologic leukemic-free state (MLFS).
Bears Say
Clinical PerformanceMP0533 has not yet shown itself to have competitive outcomes in AML / MDS.
Investor SentimentInvestors could wait for de-risking data before entering the stock.
Management StrategyManagement mentioned that they may need to dose higher to address single-tumor associated antigen (TAA) positive cells for durable efficacy.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
2.33% Other Institutional Investors
97.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.32 and its highest was $12.70 in the past 12 months.
What is Molecular Partners’s market cap?
Currently, no data Available
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Mar 12, 2025 which is in 152 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Aug 26, 2024. The company reported -$0.524 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.524.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 36,694,040 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.524 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.793%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
---
Molecular Partners Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.70 (62.11% Upside)
$7.70 (62.11% Upside)
Blogger Sentiment
Bullish
MOLN Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.66%
12-Months-Change
Fundamentals
Return on Equity
-32.16%
Trailing 12-Months
Asset Growth
-26.30%
Trailing 12-Months
Company Description
Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
---
MOLN Company Deck
---
MOLN Earnings Call
Q2 2024
0:00 / 0:00
---
MOLN Stock 12 Month Forecast
Average Price Target
$7.70
▲(62.11% Upside)
Technical Analysis
Best Analysts Covering MOLN
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+8.80%
initiated a buy rating 4 days ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +8.80% per trade.
---